Evgeny Zaytsev

Dr. Evgeny Zaytsev is a successful venture capitalist with twenty years of investment experience in life sciences. He is a Co-founder and general partner at Helix Ventures (Palo Alto, California), a venture firm investing exclusively in novel therapeutic opportunities (biopharmaceuticals and medical devices), and formerly a managing partner at RMI Partners (Palo Alto, California). Prior to Helix, he was a partner of the venture capital pioneer Pitch Johnson at Asset Management Company, one of the oldest venture firms in Silicon Valley. Dr. Zaytsev is involved in more than 30 investments, including such success stories of venture capital as Transcend Medical (acquired by Alcon), Clearside Biomedical (IPO NASDAQ: CLSD), Coherus Biosciences (IPO NASDAQ: CHRS), BiPar Sciences (acquired by Sanofi-aventis), Chimerix (IPO NASDAQ: CMRX), Fusion Medical Technologies (acquired by Baxter), MicroVention (acquired by Terumo Corp), TriVascular (acquired by Boston Scientific). He has been a Board Member of a number of public and private companies in the US and Russia. Evgeny Zaytsev is an active business community leader in Russia and Silicon Valley. He was one of the founders and the first president of the US-Russia Technology Symposium at Stanford University (now Global Technology Symposium), and the annual Silicon Valley Open Doors investment conference. Evgeny Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital, and biotechnology. Evgeny Zaytsev received his M.D. in 1991 and his Ph.D. in Medicine in 1993, both from the Altai State Medical University. He earned his MBA from the Stanford Graduate School of Business (California) in 2002.